System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Epublish 5 citations

PubMed: 36588810 DOI: 10.3892/etm.2022.11756

Effects of inhaled β‑caryophyllene on vascular stiffness in smokers: A randomized, double‑blind, placebo‑controlled trial.

Exp Ther Med 25(1):57

Authors: Kazuya Yamada, Kohei Toyota, Yamato Tsunoda, Yoshiharu Matahira, Shinichi Matsumura, Yuri Yoshioka, Nobuhiro Zaima, Naoki Unno

Affiliations

  • Sunsho Pharmaceutical Co. Ltd. Fuji, Shizuoka 419-0201, Japan.
  • Inabata Koryo, Co. Ltd. Osaka, Osaka 532-0027, Japan.
  • Department of Applied Biological Chemistry, Kindai University, Nara, Nara 631-8505, Japan.
  • Agricultural Technology and Innovation Research Institute, Kindai University, Nara, Nara 631-8505, Japan.
  • Division of Vascular Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka 431-3192, Japan.
  • Division of Vascular Surgery, Hamamatsu Medical Center, Hamamatsu, Shizuoka 432-8580, Japan.

Abstract

Approximately 1.14 billion smokers worldwide are at risk of developing tumors, cardiovascular diseases and respiratory diseases. Smoking cessation is the first choice of health care; however, the disease should be attenuated in individuals who never stop smoking, which escalates medical costs. Therefore, alternative options are needed to manage the social burden. The present study proposed an alternative method to prevent such diseases by inhalation of β-caryophyllene (BCP). A placebo-targeted, dose-searching, double-blind, parallel-group comparative study was conducted on 19 subjects. The BCP intervention was performed using a flavor capsule inserted in a cigarette filter. The primary endpoint was the reducibility of brachial-ankle pulse wave velocity (baPWV). The secondary endpoints were confirmation of the bioavailability of BCP inhalation with cigarette smoke, confirmation of the effect of BCP inhalation on respiratory function, and association between respiratory function and blood concentration and baPWV reduction. The BCP concentration in the blood reached 4 ng/ml in the BCP 15% group 10 min after inhalation. The baPWV decreased in BCP-inhaling subjects whose initial baPWV was >1,300 cm/sec. The correlation analyses revealed that the higher the forced expiratory volume in 1 sec, the better the transition of baPWV. Inhaled BCP with cigarette smoke could reduce the baPWV and the risk of cardiovascular diseases in smokers. These findings indicated that with the introduction of BCP capsule-cigarettes in the future, smokers will be able to take care of their health, which may help reduce national medical costs. BCP microcapsules placed in cigarette wrapping paper may possibly reduce the risk of sidestream smoke and contribute to improved public health. This clinical research was retrospectively registered in the University Hospital Medical Information Network (UMIN)-Clinical Trials Registry with the following identifications: UMIN000048510 and UMIN000048512 on August 15, 2022.

MeSH

Risk, Cardiovascular Diseases, Smoke, Blood, Vascular Stiffness, Inhalation, Smokers

Cited by